Significant Legal Action for Investors of PROCEPT BioRobotics Corporation Amidst Major Stock Decline

Legal Alert: PRCT Investors' Lawsuit Unveiled

On September 3, 2026, investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) were made aware of a securities class action lawsuit that has been initiated on behalf of shareholders who made purchases between February 28, 2024, and February 25, 2026. This announcement arises in response to the alarming decline in PRCT shares, which plummeted over 75%, dropping from approximately $100 per share to under $25 after the class period. Such a significant loss denotes more than $75 per share, thus raising concerns about the company's governance and compliance with securities regulations.

The lawsuit was published by SueWallSt, a firm dedicated to protecting shareholder rights. Investors who believe they may qualify to recover losses can contact Joseph E. Levi, Esq utilizing the resources provided by SueWallSt.

The Nature of the Allegations

The suit specifically cites claims against high-ranking officials at PROCEPT BioRobotics, including former CEO Reza Zadno and CFO Kevin Waters. Allegations suggest that these executives played critical roles in certifying and managing public statements that misrepresented the company's true financial health and operational efficacy.

According to the complaint, investors relied heavily on optimistic public assertions regarding handpiece utilization and procedure demands, which were pivotal for the company's revenue model that heavily depended on disposable handpiece sales linked to the AquaBeam Robotic Systems. The plaintiffs argue that the executive team misled the investing public about the company's performance through exaggerated claims, which ultimately lead to shareholder losses when the truth about lower-than-expected demand became apparent.

The legal action points to control person liability under Section 20(a), indicating that the senior leaders held responsibility for the integrity of disclosures associated with SEC filings and earnings reports. Additionally, they allegedly downplayed the impacts of discount-driven bulk ordering which resulted in overstated inventory levels, indicating a disconnect between reported sales and actual consumer demand.

Placing the investigation in further context, the lawsuit highlights that during the class period, PROCEPT BioRobotics's field inventory grew to more than 10,000 units unsold, raising red flags about unsustainable sales practices.

Sarbanes-Oxley Concerns

An essential aspect of the lawsuit involves SP Section 302 and 906 certifications under Sarbanes-Oxley. Given that corporate disclosures are expected to be accurate and comprehensive, the omission of key information regarding discount programs and inventory levels may have completely misled investors, undermining their trust in the company's public statements.

Joseph E. Levi, the attorney representing the plaintiff's interests, stated, "Corporate officers have a duty to ensure their companies' public statements are accurate and complete. Here, it is alleged that investors were not informed about critical details concerning handpiece demand and inventory challenges, which contributed to the subsequent dramatic loss in share value."

Important Deadlines and Participation

Affected investors wishing to act must file by September 22, 2026, to be considered for lead plaintiff status. It is crucial to note that even those who have already sold their shares, provided they were bought during the class period, may still be eligible for participation in the lawsuit and potential recovery of losses.

For those concerned about how to participate, it's worth noting that there are no upfront costs for consulting with SueWallSt; they operate on a contingency basis, meaning no legal fees are paid until the case has been resolved successfully.

Conclusion

This securities lawsuit against PROCEPT BioRobotics Corporation signals a significant moment for shareholders seeking justice following a precarious investment. As developments unfold, those implicated in misleading shareholders should be held accountable, promoting transparency and adherence to regulatory standards essential for maintaining investor trust in the marketplace.

Investors are encouraged to reach out to the law firms involved for additional information regarding their rights and potential recovery pathways following this troubling incident in the biotech sector.
Contact details for representatives and additional FAQs can be found through the legal advisory firm's platform.

For inquiries, call (888) SueWallSt or email [email protected]